These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 26610437)

  • 1. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
    Kim SY; Yang EG
    Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases.
    Koivunen P; Serpi R; Dimova EY
    Pharmacol Res; 2016 Dec; 114():265-273. PubMed ID: 27832958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
    Strowitzki MJ; Cummins EP; Taylor CT
    Cells; 2019 Apr; 8(5):. PubMed ID: 31035491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
    Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
    Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
    Tanaka T; Eckardt KU
    Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia.
    Xu J; Ding X; Fu Y; Meng Q; Wang L; Zhang M; Xu C; Chen S; Aliper A; Ren F; Zhavoronkov A; Ding X
    J Med Chem; 2024 Jan; 67(2):1393-1405. PubMed ID: 38189253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells.
    Singh L; Aldosary S; Saeedan AS; Ansari MN; Kaithwas G
    Drug Discov Today; 2018 Nov; 23(11):1873-1882. PubMed ID: 29772209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
    Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Zafar MU; Badimon JJ
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1187-1196. PubMed ID: 34533692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolyl hydroxylase inhibitors protect from the bone loss in ovariectomy rats by increasing bone vascularity.
    Liu X; Tu Y; Zhang L; Qi J; Ma T; Deng L
    Cell Biochem Biophys; 2014 May; 69(1):141-9. PubMed ID: 24242187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Hypoxia-Inducible Factor-1 (HIF-1) and Regulatory Prolyl Hydroxylase (PHD) Enzymes Following Hypoxic-Ischemic Injury in the Neonatal Rat.
    Chu HX; Jones NM
    Neurochem Res; 2016 Mar; 41(3):515-22. PubMed ID: 26108712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Oxoglutarate regulates binding of hydroxylated hypoxia-inducible factor to prolyl hydroxylase domain 2.
    Abboud MI; McAllister TE; Leung IKH; Chowdhury R; Jorgensen C; Domene C; Mecinović J; Lippl K; Hancock RL; Hopkinson RJ; Kawamura A; Claridge TDW; Schofield CJ
    Chem Commun (Camb); 2018 Mar; 54(25):3130-3133. PubMed ID: 29522057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat.
    Figg WD; McDonough MA; Chowdhury R; Nakashima Y; Zhang Z; Holt-Martyn JP; Krajnc A; Schofield CJ
    ChemMedChem; 2021 Jul; 16(13):2082-2088. PubMed ID: 33792169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
    Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
    Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Andrographolide inhibits hypoxia-induced HIF-1α-driven endothelin 1 secretion by activating Nrf2/HO-1 and promoting the expression of prolyl hydroxylases 2/3 in human endothelial cells.
    Lin HC; Su SL; Lu CY; Lin AH; Lin WC; Liu CS; Yang YC; Wang HM; Lii CK; Chen HW
    Environ Toxicol; 2017 Mar; 32(3):918-930. PubMed ID: 27297870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daprodustat: First Approval.
    Dhillon S
    Drugs; 2020 Sep; 80(14):1491-1497. PubMed ID: 32880805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
    Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF-prolyl hydroxylases and cardiovascular diseases.
    Sen Banerjee S; Thirunavukkarasu M; Tipu Rishi M; Sanchez JA; Maulik N; Maulik G
    Toxicol Mech Methods; 2012 Jun; 22(5):347-58. PubMed ID: 22424133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Fluorescent Benzo[g]isoquinoline-Based HIF Prolyl Hydroxylase Inhibitor for Cellular Imaging.
    Mayer M; Fey K; Heinze E; Wick CR; Abboud MI; Yeh TL; Tumber A; Orth N; Schley G; Buchholz B; Clark T; Schofield CJ; Willam C; Burzlaff N
    ChemMedChem; 2019 Jan; 14(1):94-99. PubMed ID: 30380199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors.
    Holt-Martyn JP; Chowdhury R; Tumber A; Yeh TL; Abboud MI; Lippl K; Lohans CT; Langley GW; Figg W; McDonough MA; Pugh CW; Ratcliffe PJ; Schofield CJ
    ChemMedChem; 2020 Feb; 15(3):270-273. PubMed ID: 31751494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.